Effects of angiotensin-converting enzyme inhibitor during warm blood cardioplegia

被引:9
|
作者
Hayashida, N [1 ]
Chihara, S [1 ]
Tayama, E [1 ]
Yokose, S [1 ]
Akasu, K [1 ]
Kai, E [1 ]
Aoyagi, S [1 ]
机构
[1] Kurume Univ, Dept Surg, Fukuoka, Japan
来源
ANNALS OF THORACIC SURGERY | 2000年 / 70卷 / 02期
基金
日本学术振兴会;
关键词
D O I
10.1016/S0003-4975(00)01390-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Effects of captopril, an angiotensin-converting enzyme inhibitor, during warm blood cardioplegia were assessed in the blood-perfused, isolated rat heart. Methods. The isolated hearts were arrested for 60 minutes with warm blood cardioplegia given at 20-minute intervals and were reperfused for 60 minutes. The control group (n = 10) received standard cardioplegia and the captopril group (n = 10) received cardioplegia supplemented with captopril (2 mmol/L). Cardiac function, myocardial metabolism, and cardiac release of circulating adhesion molecules were assessed before and after cardioplegic arrest. Results. Left ventricular end-diastolic pressure and -dp/dt were significantly (p < 0.05) lower and coronary blood flow was significantly (p < 0.05) greater in the captopril group than the control group during reperfusion. The captopril group resulted in significantly (p < 0.05) less cardiac release of lactate, thiobarbituric acid reactive substances during reperfusion. Cardiac release of intercellular adhesion molecule-1 was significantly (p < 0.05) less in the captopril group at 60 minutes of reperfusion. Conclusions. The results suggest that supplementation of captopril during warm blood cardioplegia provides superior myocardial protection by suppressing lipid peroxidation and leukocyte-endothelial cell interaction during reperfusion. (C) 2000 by The Society of Thoracic Surgeons.
引用
收藏
页码:627 / 632
页数:6
相关论文
共 50 条
  • [31] ENALAPRIL - A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    WEINTRAUB, M
    EVANS, P
    HOSPITAL FORMULARY, 1985, 20 (07): : 796 - &
  • [32] Angiotensin-converting enzyme inhibitor-associated angioedema
    Shin, Byol
    Lockey, Richard E.
    ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL-JOURNAL OF THE WORLD ALLERGY ORGANIZATION, 2007, 19 (04): : 164 - 165
  • [33] Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
    Wilkerson, R. Gentry
    Winters, Michael E.
    EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2022, 40 (01) : 79 - 98
  • [34] Mesenteric Angioedema Induced by Angiotensin-Converting Enzyme Inhibitor
    Gill, Inayat
    Shaheen, Aciel A.
    Edhi, Ahmed I.
    Cappell, Mitchell S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1511 - S1512
  • [35] Angiotensin-converting enzyme inhibitor related angioedema and the anaesthetist
    Rai, MR
    Amen, F
    Idrees, F
    ANAESTHESIA, 2004, 59 (03) : 283 - 289
  • [36] LISINOPRIL - A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    ARMAYOR, GM
    LOPEZ, LM
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (05): : 365 - 372
  • [37] Perioral angioedema associated with angiotensin-converting enzyme inhibitor
    Peacock, ME
    Park, DS
    Swiec, GD
    Erley, KJ
    JOURNAL OF PERIODONTOLOGY, 2005, 76 (04) : 651 - 654
  • [38] ENALAPRIL, A NONSULFHYDRYL ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    VLASSES, PH
    LARIJANI, GE
    CONNER, DP
    FERGUSON, RK
    CLINICAL PHARMACY, 1985, 4 (01): : 27 - 40
  • [39] CONSEQUENCES OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR OVERDOSE
    VARUGHESE, A
    TAYLOR, AA
    NELSON, EB
    AMERICAN JOURNAL OF HYPERTENSION, 1989, 2 (05) : 355 - 357
  • [40] Benefit of aspirin plus angiotensin-converting enzyme inhibitor
    Baigent, C
    Collins, R
    Peto, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1474 - 1475